All releases of Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
Ordered by date, latest to top
-
Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
First-line treatment of adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant: SMC2804 (Latest release)
Published on 29 Jul 2025
-
Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
Systemic anti-cancer therapy (SACT) after CDK 4/6 inhibitors for the treatment of metastatic / locally advanced breast cancer (SMC2807)
Published on 22 Jul 2025
-
Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
First-line platinum-based chemotherapy followed by maintenance treatment for advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer: SMC2799
Published on 24 Jun 2025
-
Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
First-line treatment for primary advanced or recurrent endometrial cancer: SMC2767 (pembrolizumab with carboplatin & paclitaxel) & SMC2797 (durvalumab with carboplatin & paclitaxel)
Published on 29 Apr 2025
-
Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
First line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC): information for SMC decision SMC2735
Published on 04 Mar 2025
-
Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
First-line treatment of adults with advanced non-small cell lung cancer (NSCLC) whose tumours have presumed EGFR mutations: information for SMC decision SMC2736
Published on 04 Mar 2025